RT @vthijs: The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating…
RT @vthijs: The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating…
RT @vthijs: The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating…
RT @vthijs: The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating…
RT @vthijs: The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating…
RT @vthijs: The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating…
RT @vthijs: The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating…
RT @vthijs: The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating…
The SPARCL trial still 'sparkling' after almost 15 years. Analysis of total (not only first vascular) events shows accumulating benefits over time. https://t.co/K4yMoCcICd https://t.co/0banUcjWNn
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
Que no será con la Rosuvastatina 🤔🤔🤔🤔🤔🤔🤔
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
RT @edurontoFF: .Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemic…
.Estudio SPARCL En pacientes con ACV o AIT reciente, la atorvastatina reduce dramaticamente la chance de un evento isquemico en todos los territorios. Se previenen 20 eventos vasculares cada 100 pacientes tratados!!!! https://t.co/tzs9kC9IKp https://t.co/E
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories https://t.co/pYSEPxjuOA
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
RT @ValleAlfonso: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascul…
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories #SPARCL Trial ⏱6 years➡️ 20 vascular events per 100 👤 were avoided with atorvastatin treatment. 📂https://t.co/0SowiEDsgJ @secardiologia https://t.co/lJDBGmQec1
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
RT @pnatarajanmd: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories https://t.co/8u450MAWh0 @JACCJourna…
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
RT @pnatarajanmd: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories https://t.co/8u450MAWh0 @JACCJourna…
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories https://t.co/8u450MAWh0 @JACCJournals https://t.co/TXIvQ607cf
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
RT @Drlipid: SPARCL data - In pts with recent CVA/TIA, the total # vascular events prevented w atorvastatin was >2X number of 1st events p…
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories | JACC: Journal of the American College of Cardiology https://t.co/XBvh7sttTy
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
RT @jvillacastin: Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attac…
Atorvastatin Reduces First and Subsequent Vascular Events: In participants with recent stroke or transient ischemic attack, the total number of vascular events prevented with atorvastatin was more than twice the number of first events prevented. https://t.
RT @Drlipid: SPARCL data - In pts with recent CVA/TIA, the total # vascular events prevented w atorvastatin was >2X number of 1st events p…
@50Fitty @LukeEdwards504
SPARCL data - In pts with recent CVA/TIA, the total # vascular events prevented w atorvastatin was >2X number of 1st events prevented. This captures the totality of atorvastatin clinical efficacy https://t.co/zVWtKTTpyH
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories in the SPARCL Trial. https://t.co/Zhs42mvzSi
SPARCL trial - total events reduced dramatically. https://t.co/Wx0V9hkqgq